Current Legal Status: TB-500 in 2026
TB-500 has a straightforward legal status: available as a research chemical, not restricted by the FDA, and not available through the compounding pharmacy system. Its primary regulatory concern is the WADA prohibition for tested athletes.
Federal Legal Status
| Status | TB-500 |
|---|---|
| FDA-approved | No |
| Category 2 restricted | No |
| Controlled substance | No |
| Compounding available | Generally no |
| Research chemical available | Yes |
| WADA prohibited | Yes |
Comparison: TB-500 vs BPC-157 Legal Status
Since TB-500 and BPC-157 are commonly used together (the Wolverine Stack), understanding their comparative legal status matters:
| Factor | TB-500 | BPC-157 |
|---|---|---|
| FDA-approved | No | No |
| Category 2 | No | Yes (Sept 2023) |
| Compounding available | Not typically | No (banned) |
| Research chemical | Available | Available |
| WADA banned | Yes (earlier) | Yes (Jan 2022) |
| Controlled substance | No | No |
Key difference: BPC-157 was hit by Category 2 restrictions because it was widely compounded by pharmacies and prescribed by clinics. TB-500 avoided this because it was primarily a research chemical product from the start — fewer pharmacies compounded it, so the FDA had less reason to act.
Access
Research Chemical (Primary Route)
| Feature | Details |
|---|---|
| Product | TB-500 lyophilized powder, typically 5mg or 10mg vials |
| Prescription | Not required |
| Cost | $30-60 per 5mg vial |
| Quality | Varies — CoA verification essential |
| Administration | Subcutaneous injection after reconstitution with BAC water |
Quality Verification
| Check | What to Look For |
|---|---|
| Purity | >98% via HPLC on third-party CoA |
| Identity | Mass spectrometry confirming MW ~4963 Da |
| Sterility | Endotoxin testing for injectable products |
| Appearance | White lyophilized powder (not clumped or discolored) |
WADA Prohibition
TB-500 has a longer prohibition history than many other peptides:
| Event | Detail |
|---|---|
| Equine sports ban | TB-500 was banned in horse racing before human sports — high-profile cases in Australian racing brought attention |
| WADA prohibition | Prohibited under S2 — Peptide Hormones, Growth Factors, Related Substances and Mimetics |
| Timing | Prohibited at all times (in-competition and out-of-competition) |
| Detection | Detectable via urine testing |
The Horse Racing Connection
TB-500 gained notoriety through horse racing doping scandals, particularly in Australia. Trainers used TB-500 for equine injury recovery. When racing authorities cracked down, the peptide’s profile was raised, which contributed to WADA including it on the human Prohibited List. This history means TB-500 is more “well-known” to anti-doping authorities than less prominent peptides.
Regulatory Outlook
Low Risk of Near-Term Restriction
TB-500 is unlikely to face additional regulatory action in 2026-2027:
- Not widely compounded — the FDA’s Category 2 tool is less relevant
- No pharmaceutical competition — no brand-name product pushing for enforcement
- Research chemical market — the FDA has limited jurisdiction over research chemicals that don’t make therapeutic claims
- Lower visibility — compared to GLP-1 drugs and BPC-157, TB-500 attracts less regulatory attention
Possible Long-Term Risks
- Broader peptide legislation — if Congress passes legislation targeting research peptides broadly, TB-500 could be swept in
- DSHEA enforcement — if TB-500 appears in supplement products (it shouldn’t, but sometimes does), FDA enforcement could increase
- International changes — regulatory action in other countries could affect supply from international manufacturers
The Wolverine Stack Consideration
If you use the Wolverine Stack (BPC-157 + TB-500), the legal consideration is that:
- TB-500 remains unrestricted beyond WADA
- BPC-157 is Category 2 restricted (no compounding pharmacy access)
- Both are available as research chemicals
- Both are prohibited by WADA
The Category 2 restriction on BPC-157 does not affect TB-500 access. You can still obtain both from research chemical vendors.
Related Resources
- TB-500 Protocol — dosing, loading phase, and administration
- BPC-157 vs TB-500 — head-to-head comparison
- BPC-157 Legal Status — BPC-157 regulatory guide
- Wolverine Stack — BPC-157 + TB-500 combination protocol
- Peptide Legality & FDA Status Guide — complete overview
Frequently Asked Questions
Is TB-500 legal in 2026? +
Yes. TB-500 (a synthetic fragment of Thymosin Beta-4) is legal to purchase as a research chemical in the United States. It is not FDA-approved, not a controlled substance, and has not been placed on the FDA's Category 2 list. Unlike BPC-157, TB-500 has not faced specific compounding restrictions, though it was not widely compounded to begin with.
What is the difference between TB-500 and Thymosin Beta-4? +
TB-500 is a synthetic peptide fragment that contains the active region (amino acids 17-23, the actin-binding domain) of the full-length Thymosin Beta-4 protein. They are sometimes used interchangeably in the peptide community, but they are different products. The legal status is the same for both — neither is FDA-approved or controlled.
Is TB-500 banned by WADA? +
Yes. Both TB-500 and Thymosin Beta-4 are on the WADA Prohibited List under S2, prohibited at all times. TB-500 was one of the earlier peptides targeted by WADA, partly due to its use in horse racing (it was banned in equine sports before being explicitly listed by WADA for human athletes).
Can I get TB-500 from a compounding pharmacy? +
TB-500 is generally not available from compounding pharmacies. Unlike CJC-1295/Ipamorelin or sermorelin, TB-500 was never widely adopted by the compounding pharmacy and clinical prescription model. The primary access route is through research chemical vendors.
Could TB-500 be placed on the FDA Category 2 list? +
Possible but lower priority. TB-500 is not widely compounded, so the FDA's Category 2 mechanism (which restricts compounding pharmacies) has less impact. If the FDA expands regulatory action beyond compounding restrictions, TB-500 could be affected, but it is a lower priority target than compounds with larger clinical and compounding markets.